Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial
SUNRISE is a double-blind phase 3 trial across 63 sites in 12 countries testing whether tezepelumab reduces maintenance oral corticosteroids while preserving asthma control. Interpretation should integrate overall and eosinophil subgroups, exacerbations and safety.